Showing results (21-30 of 178) with videos related to

Sort By:
Pageof 18
Current Pharmaceutical Design|April 10, 2013
Myocardial infarction after rituximab treatment for rheumatoid arthritis: Is there a link?Alper M van Sijl, Wilfred van der Weele, Michael T Nurmohamed
Plos One|February 6, 2014
Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort studyAlper M van Sijl, Maarten Boers, Alexandre E Voskuyl, et al.
Rheumatology (Oxford, England)|December 11, 2012
Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort studyCharlotte L M Krieckaert, Michael T Nurmohamed, Gertjan Wolbink, et al.
Clinical and Experimental Rheumatology|June 6, 2023
Cardiovascular risk management in gout patients: do patients benefit from screening in secondary care?Daisy Vedder, Maaike Heslinga, Carla A Wijbrandts, et al.
The Journal of Rheumatology|May 3, 2013
High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort studyAnna Jamnitski, Johannes H Levels, Inge A van den Oever, et al.
Rheumatology (Oxford, England)|November 14, 2020
A neutrophil signature is strongly associated with increased cardiovascular risk in goutDaisy Vedder, Martijn Gerritsen, Michael T Nurmohamed, et al.
The Journal of Rheumatology|June 3, 2017
The Effects of 5-year Etanercept Therapy on Cardiovascular Risk Factors in Patients with Psoriatic ArthritisRabia Agca, Maaike Heslinga, Eva L Kneepkens, et al.
Therapeutic Advances in Musculoskeletal Disease|August 2, 2013
Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinionInge A M van den Oever, Alper M van Sijl, Michael T Nurmohamed
Rheumatic Diseases Clinics of North America|October 23, 2012
Comorbidities in patients with spondyloarthritisIrene E van der Horst-Bruinsma, Michael T Nurmohamed, Robert B M Landewé
The Journal of Rheumatology|September 15, 2023
Changes in Tumor Necrosis Factor Inhibitor Drug Survival in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Over 15 YearsIngrid M Visman, Sadaf Atiqi, Maarten Boers, et al.
Pageof 18